Correlation Between DexCom and Lineage Cell

Can any of the company-specific risk be diversified away by investing in both DexCom and Lineage Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DexCom and Lineage Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between DexCom Inc and Lineage Cell Therapeutics, you can compare the effects of market volatilities on DexCom and Lineage Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DexCom with a short position of Lineage Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of DexCom and Lineage Cell.

Diversification Opportunities for DexCom and Lineage Cell

-0.6

Correlation Coefficient

DexCom  Lineage Cell

Excellent diversification

The 3 months correlation between DexCom and Lineage is -0.6. Overlapping area represents the amount of risk that can be diversified away by holding DexCom Inc and Lineage Cell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lineage Cell Therapeutics and DexCom is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DexCom Inc are associated (or correlated) with Lineage Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lineage Cell Therapeutics has no effect on the direction of DexCom i.e., DexCom and Lineage Cell go up and down completely randomly.

Pair Corralation between DexCom and Lineage Cell

Given the investment horizon of 90 days DexCom Inc is expected to generate 0.35 times more return on investment than Lineage Cell. However, DexCom Inc is 2.84 times less risky than Lineage Cell. It trades about 0.07 of its potential returns per unit of risk. Lineage Cell Therapeutics is currently generating about -0.09 per unit of risk. If you would invest  7,236  in DexCom Inc on September 3, 2024 and sell it today you would earn a total of  563.00  from holding DexCom Inc or generate 7.78% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

DexCom Inc  vs.  Lineage Cell Therapeutics

DexCom Inc

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in DexCom Inc are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating fundamental indicators, DexCom may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Lineage Cell Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lineage Cell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with DexCom and Lineage Cell

The main advantage of trading using opposite DexCom and Lineage Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DexCom position performs unexpectedly, Lineage Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lineage Cell will offset losses from the drop in Lineage Cell's long position.

The idea behind DexCom Inc and Lineage Cell Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.